AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01350102
Drug: AmeriGel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.
Trial: NCT00092378
Drug: MK0966, rofecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00092378
Drug: Comparator: diclofenac sodium, placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01316809
Drug: AZD8055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will start at 120 mg once daily
Trial: NCT01748578
Drug: EBI-005-1
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo
Trial: NCT01748578
Drug: EBI-005-1 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02640807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
Trial: NCT00515112
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00144235
Drug: Pharmaton PHL 00749
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00144235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02322372
Drug: Femoral blockade
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
Trial: NCT02322372
Drug: Intrathecal anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with heavy bupivacaine
Trial: NCT02767999
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg of fluoxetine capsule per day from D0 to D90
Trial: NCT02767999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cellulose placebo per day from D0 to D90
Trial: NCT01435499
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m2 given as a single dose, intravenously, one day prior to each of the 4 vaccinations to patients in cohort C only
Trial: NCT01001806
Drug: Ketorolac Tromethamine 0.45%
RxNorm normalized name: KETOROLAC TROMETHAMINE 0.45%PF OPH 0.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
Trial: NCT00443755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
Trial: NCT03533803
Drug: Indomethacin 100Mg Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 100Mg Suppository will be given 1 to 2 hours before embryo transfer in cases with difficult mock embryo transfer in the active comparator group.
Trial: NCT01001806
Drug: bromfenac 0.09%
RxNorm normalized name: Bromfenac 0.09% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One day pre operative 1 drop BID then 3 doses pre op day of surgery
Trial: NCT01001806
Drug: nepafenac 0.1%
RxNorm normalized name: NEPAFENAC 0.1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop BID, 1 day pre operative and then 3 doses the day of surgery
Trial: NCT00045591
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg PO bid
Trial: NCT00045591
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg PO bid
Trial: NCT04234594
Drug: Vectibix®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg intravenous (IV) infusion only once，on the first day.
Trial: NCT00185783
Drug: Hydrocortisone Administration (Standard of Care Therapy)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01055470
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.
Trial: NCT01055470
Drug: Lornoxicam
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
Trial: NCT00003394
Drug: endocrine-modulating drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02603107
Drug: DRV
RxNorm normalized name: Urinal Male Drv RTLPC23201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg tablet administered orally once daily with food
Trial: NCT02603107
Drug: ATV/co
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300/150 mg FDC tablet administered orally once daily with food
Trial: NCT02603107
Drug: DRV/co
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800/150 mg FDC tablet administered orally once daily with food
Trial: NCT02603107
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/300 mg FDC tablet administered orally once daily without regard to food
Trial: NCT02603107
Drug: ABC/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600/300 mg tablet administered orally once daily with or without regard to food
Trial: NCT02603107
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/200/25 mg FDC tablet administered orally once daily without regard to food
Trial: NCT00019630
Drug: doxorubicin HCl liposome
RxNorm normalized name: DOXORUBICIN HCL LIPOSOME 2MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01862614
Drug: Articaine Hydrochloride + Epinephrine
RxNorm normalized name: articaine hydrochloride / epinephrine Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01862614
Drug: Buffered Articaine Hydrochloride + Epinephrine
RxNorm normalized name: articaine hydrochloride / epinephrine Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02454868
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil for intubation without neuromuscular blockade
Trial: NCT04622072
Drug: XZP-5809-TT1 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single tartrate of XZP-5809
Trial: NCT01621321
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
Trial: NCT04967859
Drug: 0.1% gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
Trial: NCT04967859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients using placebo ointment at the exit site of the hemodialysis catheter
Trial: NCT00038311
Drug: PN-152,243)/PN-196,444
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04687566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will take the placebo pills, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
Trial: NCT03647072
Drug: CHOP Plus Lanzoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP plus Lanzoprazole 60 mg
Trial: NCT00004901
Drug: ethynyluracil
RxNorm normalized name: 5-Ethynyluracil
DrugBank: Eniluracil (DB03516)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004901
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01638403
Drug: BF2.649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).~Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
Trial: NCT01638403
Drug: palcebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
Trial: NCT03604575
Drug: Humalog®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00033306
Drug: Fluoropyrimidine
RxNorm normalized name: Fluoropyrimidine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01281956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00359177
Drug: GW679769
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning
Trial: NCT00939237
Drug: Ateronon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
Trial: NCT00939237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00999700
Drug: docetaxel - cisplatin - 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
Trial: NCT02488967
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02488967
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01538394
Drug: Placebo (nicotine patches)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01216904
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch to be worn 16 hours per day
Trial: NCT02112799
Drug: NVR 3-778
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02112799
Drug: Placebo for NVR 3-778
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic the NVR 3-778 capsule
Trial: NCT01257386
Drug: Asacol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg tablets
Trial: NCT02456961
Drug: Dextralink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin 0,1% + Dextran T-500
Trial: NCT00984334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03373318
Drug: Plasmalyte
RxNorm normalized name: PLASMALYTE A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose and the speed of administration depend on the age, weight, clinical and biological status of the patient and the concomitant treatment. The recommended dose for adults, the elderly and adolescents: from 500 ml to 3 liters / 24 hours.
Trial: NCT02889809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
Trial: NCT02889809
Drug: Short Acting Beta 2 Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
Trial: NCT02581826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No column specified.
Trial: NCT00003116
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide IV twice a day on days -4 and -3
Trial: NCT01975259
Drug: Oral Glucose Tolerance test (75g 2-hour)
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution \& have glucose levels recorded up to every 30 mins for 2hours
Trial: NCT01975259
Drug: Modified Oral Glucose Tolerance Test (50g 4-hours)
RxNorm normalized name: glucose 0.4 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution \& have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
Trial: NCT01975259
Drug: Hyperglycemic clamp with placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).~After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving.
Trial: NCT03162094
Drug: Placebo (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular topical administration of placebo (vehicle Ophthalmic Solution)
Trial: NCT01132222
Drug: Ibuprofen + Pseudoephedrine Hydrochloride
RxNorm normalized name: ibuprofen / pseudoephedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
Trial: NCT01746199
Drug: cotrimoxazole daily prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01041677
Drug: R256918
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg capsule twice daily
Trial: NCT01041677
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule twice daily
Trial: NCT01041677
Drug: R256918
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg capsule twice daily
Trial: NCT00464295
Drug: Capecitabine in HCC
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00307671
Drug: prednisone, methylprednisolone,cyclophosphamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment conventional
Trial: NCT00307671
Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reduction dose
Trial: NCT00307671
Drug: Mycophenolate mofetil,methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in the treatment conventional and in the reduction dose
Trial: NCT02035488
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
Trial: NCT03320941
Drug: LIK066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIK066 will be supplied in different doses as tablets to be taken orally daily.
Trial: NCT03320941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as tablets to be taken daily orally.
Trial: NCT01753323
Drug: KAF156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAF156 was supplied as tablets for oral use.
Trial: NCT00774306
Drug: phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
Trial: NCT00927537
Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients under daily life treatment receiving Kinzalplus according to local drug information.
Trial: NCT03362684
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-4 every 2 weeks
Trial: NCT00964015
Drug: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03745651
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib matching vehicle cream.
Trial: NCT02884921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03360071
Drug: Allergen Immunotherapy Extract
RxNorm normalized name: Allergen immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen Immunotherapy treatment mixture to be delivered subcutaneously
Trial: NCT01443546
Drug: Lupron Trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leuprolide acetate 2 mg SQ
Trial: NCT03490942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo solution is a non-active formulation containing excipients only.
Trial: NCT02503839
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclooxygenase-2 inhibitor. Anti-inflammatory
Trial: NCT00952016
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: study subjects will receive methotrexate intravenously on day 1 and day 8 of a 3 weekly cycle.
Trial: NCT00201214
Drug: Citrulline
RxNorm normalized name: Citrulline
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with dosage escalation study 50mg/kg, 100mg/kg, 150mg/kg IV at 6, 12, 24, 48 hours post operative. Phase II - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with 9mg/kg/hr continuous IV starting 4 hours post bolus and infusing for 48 hours or discharge from PCCU.
Trial: NCT04047849
Drug: Antibiotics, oral Azithromycin and oral Amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500mg day one followed by 250mg per day for 4 more days) and amoxicillin (500mg orally three times daily for 7 days) for a total course of seven days of antibiotic therapy
Trial: NCT01272375
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04764793 250/50 using inhaler A
Trial: NCT01272375
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04764793 250/50 using inhaler A
Trial: NCT01272375
Drug: Treatment G
RxNorm normalized name: VanaLice Lice Killing Treatment Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04764793 250/50 using inhaler B
Trial: NCT02295293
Drug: Rhus Coriaria L. (Rhus)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
Trial: NCT04362111
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days
Trial: NCT00482417
Drug: MK0359
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02522299
Drug: GSK2269557
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device. Since GSK2269557 will no longer be manufactured for use with the DISKUS device, it will be replaced with ELLIPTA Device. Subjects will receive GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
Trial: NCT02522299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device
Trial: NCT04161872
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01607294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Daily for 4 weeks
Trial: NCT01485302
Drug: SAR228810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution~Route of administration: intravenous
Trial: NCT01485302
Drug: SAR228810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Trial: NCT02704559
Drug: DWC20155
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03518034
Drug: AndroGel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: testosterone administered topically
Trial: NCT02625922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo i.v infusion
Trial: NCT01527500
Drug: LFG316
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LFG316 5 mg/50 μL solution for IVT injection,
Trial: NCT01527500
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)
Trial: NCT01110551
Drug: Placebo (SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline administered subcutaneously.
Trial: NCT01110551
Drug: Placebo (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline administered intradermally.
Trial: NCT00187122
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See Detailed Description section for description of treatment plan.
Trial: NCT00187122
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See Detailed Description section for description of treatment plan.